Einloggen
Einloggen
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registrieren
Oder einloggen mit
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

HALOZYME THERAPEUTICS, INC.

(HALO)
  Bericht
Verzögert Nasdaq  -  22:00 05.10.2022
41.66 USD   +0.26%
09.09.Halozyme Therapeutics, Inc. : Morgan Stanley bekräftigt seine Kaufempfehlung
MM
16.08.Halozyme Therapeutics preist ein erweitertes Angebot von $ 625 Millionen an wandelbaren vorrangigen Anleihen
MT
15.08.Halozyme Therapeutics bietet $500 Millionen an wandelbaren vorrangigen Anleihen mit Fälligkeit 2028
MT
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivateFonds 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über HALOZYME THERAPEUTICS, INC.
09.09.Why is the market going up this morning?
09.09.Analyst recommendations: American Water, Darktrace, Nasdaq, Rege..
01.09.Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference
19.08.Halozyme Therapeutics, Inc. : Entry into a Material Definitive Agreement, Creation of a Di..
19.08.Halozyme Therapeutics, Inc. Enters into Amendment No. 1 to the Credit Agreement
18.08.Halozyme Therapeutics Completes $720 Million Sale of 1% Convertible Senior Notes due 20..
18.08.Halozyme Therapeutics, Inc. : Entry into a Material Definitive Agreement, Creation of a Di..
16.08.Halozyme Therapeutics : Announces Upsize and Pricing of Private Offering of $625 Million o..
16.08.Halozyme Therapeutics Prices Upsized Offering of $625 Million of Convertible Senior Not..
16.08.Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Mi..
15.08.Halozyme Therapeutics to Offer $500 Million of Convertible Senior Notes Due 2028
15.08.Halozyme Therapeutics to Seek Acquisitions
15.08.Halozyme Therapeutics : The Company plans to purchase up to $200 million worth of shares c..
15.08.Halozyme Therapeutics, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
15.08.Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible ..
09.08.Halozyme Therapeutics : Q2 Earnings Snapshot
09.08.Halozyme Therapeutics : REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS - Form..
09.08.Halozyme Therapeutics : NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFO..
09.08.Transcript : Halozyme Therapeutics, Inc., Q2 2022 Earnings Call, Aug 09, 2022
09.08.Halozyme Therapeutics Q2 Adjusted EPS Drops, Revenue Gains; Company Raises 2022 Outlook
09.08.HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
09.08.HALOZYME THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
09.08.Earnings Flash (HALO) HALOZYME THERAPEUTICS Reports Q2 Revenue $152.4M, vs. Street Est ..
09.08.Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q2 EPS $0.53
09.08.Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on Decemb..
09.08.Halozyme reports second quarter 2022 financial and operating results
09.08.Halozyme Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Mon..
09.08.Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022
02.08.Halozyme Therapeutics Says Phase 3 Study Evaluating Formulation of Tecentriq with Enhan..
02.08.Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formu..
02.08.Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study E..
26.07.Halozyme to Report Second Quarter 2022 Financial and Operating Results
24.06.Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to..
24.06.Halozyme Therapeutics, Inc.(NasdaqGS:HALO) added to..
15.06.Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annua..
10.06.Genmab Seeks $405 Million in New Arbitration With Janssen
10.06.Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
08.06.Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
07.06.Halozyme Therapeutics Launches Testosterone Replacement Therapy Drug Tlando
07.06.Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testostero..
07.06.Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment fo..
24.05.Halozyme Therapeutics : Completes Antares Pharma Acquisition - Form 8-K
24.05.Halozyme Therapeutics, Inc. : Entry into a Material Definitive Agreement, Completion of Ac..
24.05.Halozyme Completes Antares Pharma Acquisition
23.05.Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..
12.05.Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
12.05.Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
10.05.Transcript : Halozyme Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
10.05.HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
10.05.Halozyme Therapeutics' Q1 Non-GAAP Earnings, Revenue Rise; Issues Full Year 2022 Guidan..
10.05.Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q1 Revenue $117.3M, vs. Street Est of..
10.05.Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on Decemb..
10.05.Halozyme Therapeutics : Q1 Earnings Snapshot
10.05.Halozyme Reports First Quarter 2022 Results
10.05.Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022
10.05.Halozyme Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March ..
06.05.Halozyme Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders (form 8-..
03.05.Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
26.04.Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares
26.04.Halozyme commences tender offer for all outstanding shares of common stock of antares p..
13.04.Halozyme Therapeutics, Inc. : Entry into a Material Definitive Agreement, Regulation FD Di..
13.04.Sector Update: Health Care Stocks Putting Up Modest Gains This Afternoon
13.04.Health Care Up Amid Deal Activity -- Health Care Roundup
13.04.Sector Update: Health Care Stocks Edging Higher Wednesday Afternoon
13.04.Top Midday Gainers
13.04.Halozyme Therapeutics : Transaction Investor Presentation
13.04.Halozyme to Acquire Antares Pharma for $960 Million; Antares Shares Surge
13.04.Wall Street Set for Muted Open as Traders Digest BlackRock, JPMorgan Earnings; Producer..
13.04.Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
13.04.Transcript : Antares Pharma, Inc., Halozyme Therapeutics, Inc. - M&A Call
13.04.Top Premarket Gainers
13.04.North American Morning Briefing: Stock Futures Tick Up Ahead of Earnings
13.04.Halozyme Therapeutics, Inc. entered into a definitive agreement to acquire Antares Phar..
08.04.Genmab Says Panel in Daratumumab Arbitration Rules in Favor of Johnson & Johnson Unit
08.04.Genmab Considers Options in Daratumumab License Row After Tribunal Rules in Favor of Ja..
05.04.Insights Value Series : Introduction
24.03.Halozyme Therapeutics Licenses Enhanze Technology to Chugai Pharmaceutical for $25 Mill..
24.03.Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and Li..
24.03.Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Co., Ltd Enters Global Collaborat..
22.03.Halozyme Therapeutics Says Argenx's Phase 3 Trial in Generalized Myasthenia Gravis Meet..
22.03.Halozyme Therapeutics Says Argenx's Phase 3 Trial in Generalized Myasthenia Gravis Achi..
22.03.Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartig..
22.03.Halozyme Therapeutics, Inc. Announces Data from Argenx's Phase 3 Adapt-Sc Study Evaluat..
21.03.Halozyme Therapeutics, Inc. : Entry into a Material Definitive Agreement, Creation of a Di..
15.03.Halozyme Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
15.03.Halozyme Appoints Moni Miyashita to Board of Directors
15.03.Halozyme Therapeutics, Inc. Appoints Moni Miyashita to Board of Directors
22.02.Halozyme Therapeutics : Q4 Earnings Snapshot
22.02.Halozyme Therapeutics to Seek M&A
22.02.Transcript : Halozyme Therapeutics, Inc., Q4 2021 Earnings Call, Feb 22, 2022
22.02.HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
22.02.Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on Decemb..
22.02.Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on Novemb..
22.02.Halozyme Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 3..
22.02.Halozyme Therapeutics Q4 Adjusted EPS, Revenue Decline; FY2022 Guidance Reiterated
22.02.Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q4 Revenue $102M, vs. Street Est of $..
22.02.Earnings Flash (HALO) HALOZYME THERAPEUTICS Posts Q4 EPS $0.42, vs. Street Est of $0.41
22.02.Halozyme Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
22.02.Halozyme reports fourth quarter 2021 and full year results
22.02.Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022
Anstehende Termine für HALOZYME THERAPEUTICS, INC.